Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide

May 31, 2026 By The ASCO Post Staff

Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ effects on cognitive function in patients with advanced prostate cancer (Abstract 5005).

Related Content